Pangen Biotech Selected as Negotiation Partner for KNIH's SFTS Therapeutic Antibody R&D Project – KRW 2.75 Billion Government Contract
Pangen Biotech has been selected as a negotiation partner for a KNIH project: 'Advancement and evaluation of non-clinical sample production system for SFTS therapeutic antibody'.
Total contract value is approximately KRW 3.545 billion (excl. VAT), of which Pangen's share (77.44%) amounts to KRW 2.745 billion, representing 20.46% of 2025 revenue (KRW 13.42 billion).
Contract period runs from signing to December 31, 2028, indicating a long-term R&D initiative.
The project involves establishing non-clinical sample production and evaluation systems for SFTS antibodies, validating Pangen's antibody development capabilities.
This award enhances technological credibility and potential future commercialization, though immediate revenue impact is limited.
[AI Comprehensive Analysis]This government R&D contract is positive for the company's long-term competitiveness but does not provide immediate earnings. The impact on share price is likely modest, but may improve sentiment in the biotech sector.
KOSDAQ Filing Information
Filing: Major Management Issues Related to Investment Decision (Selection of Negotiation Target for the Advancement of Non-Clinical Sample Production System and Evaluation Task of Therapeutic Antibodies for Severe Fever with Thrombocytopenia Syndrome (SFTS) by the Korea Disease Control and Prevention Agency, National Institute of Health)